CharlesChau

Partner

Hong Kong + 852.3189.7268

Charles Chau has represented clients in more than 100 public and private company acquisitions, joint ventures, financings, and pre-IPO investments. He advises on M&A, capital markets (including listings and public offerings), securities regulatory compliance, joint ventures, and other commercial transactions across Hong Kong, mainland China, and the Asia-Pacific region. Charles has 20 years of extensive experience in a wide variety of industry sectors, including banking and financial services, health care, biotech, retail, real estate, and manufacturing. He also has represented Chinese companies on their outbound acquisitions in the United States.

Prior to joining Jones Day in 2017, Charles acted for China CNR Corporation Limited in its US$26 billion merger with CSR Corporation Limited, which was the first merger of two companies listed in both Hong Kong and Shanghai. In addition, he worked on many IPOs and securities placement transactions, including the IPOs of Sinopharm Group, China CNR Corporation, Guodian Technology & Environment Group, and the A+H rights issue of China CITIC Bank.

Charles holds positions in several public organizations, including as an adjudicator of the Registration of Persons Tribunal and as a member of the Legal Committee and the Young Executive Club of the Hong Kong General Chamber of Commerce.

Esperienze

  • Investment Global divests shares in Daimler TruckJones Day represented Investment Global Co., Limited, a portfolio company of Beijing Auto Group, a backbone enterprise in China's automobile industry, in connection with the sale of approximately 29 million shares in Daimler Truck Holding AG, one of the world’s leading truck manufacturers (FRA:DTG) in a combination of brokerage and derivative transactions.
  • CMBC International Capital Limited underwrites US$69 million IPO by Star Plus Legend Holdings LimitedJones Day represented CMBC International Capital Limited in connection with the approximately US$69 million initial public offering of Ordinary Shares of Star Plus Legend Holdings Limited listed on The Stock Exchange of Hong Kong Limited.
  • China Post Group Limited invests $128 million in Ule Holdings LimitedJones Day advised China Post Group Limited with its $128 million investment in Ule Holdings Limited through Telpo Philatelic Company Limited ("Telpo"), a subsidiary of China Post.
  • GenScript Biotech Corporation completes US$402 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with a US$402 million follow-on offering by its Nasdaq-subsidiary Legend Biotech Corporation (NASDAQ: LEGN).
  • Hong Kong and China Power Holdings invests in Luquos Holding Limited (Luquos Cayman) seed roundJones Day represented Hong Kong and China Power Holdings Company Limited in the series seed round of financing of Luquos Holding Limited (Luquos Cayman).
  • GenScript Bio's non-wholly-owned subsidiary Probio Technology Limited raises $37 million in Series B financingJones Day represented GenScript Biotech Corporation (HK Stock Code: 1548) ("GenScript Biotech") in the $37 million Series B financing of non-wholly-owned subsidiary Probio Technology Limited ("Probio Cayman"), led by Zhenjiang High-tech Venture Capital (HK) Limited.
  • Albaugh acquires RotamJones Day advised Albaugh, LLC in the $197.5 acquisition of Rotam Global AgroSciences Limited, a company headquartered in Hong Kong and publicly listed on the Taiwan Stock Exchange.
  • LeaderMed Health Group expands pipeline with Aqualung licenseJones Day represented LeaderMed Health Group Limited in subscription of a convertible note and an exclusive license agreement with Aqualung Therapeutics Corporation ("Aqualung") to develop, manufacture, and commercialize Aqualung's clinical stage antibody product ALT-100 in eight Asian territories, including Greater China.
  • Samson Paper Holdings Limited completes US$385 million cross-border restructuringJones Day advised Samson Paper Holdings Limited (the "Company"), a Bermuda incorporated company listed on the Main Board of the Stock Exchange of Hong Kong in connection with its US$385 million Bermuda/Mainland China/Hong Kong cross-border restructuring deal (the "Restructuring").
  • GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech CorporationJones Day represented GenScript Biotech Corporation in connection with its US$344.6 million follow-on offering by its NASDAQ-subsidiary Legend Biotech Corporation.
  • LeaderMed Health Group Limited enters into joint venture and licensing agreement with OPKO Health to develop and commercialize innovative drugs in Asian countriesJones Day represented LeaderMed Health Group Limited in the formation of a joint venture and exclusive license agreement with OPKO Health, Inc. ("OPKO") to develop, manufacture, and commercialize two of OPKO's clinical stage, long-acting drug products, Oxyntomodulin and Factor VIIa-CTP, in Greater China and eight other Asian territories.
  • GenScript Biotech and its subsidiaries Legend Biotech and ProBio Cayman complete US$1.07 billion investment by Hillhouse CapitalJones Day represented GenScript Biotech Corporation (“GenScript Biotech”), its controlling shareholder GenScript Corporation, and its two subsidiaries Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) and Probio Technology Limited (“Probio Cayman”) in connection with a US$1.07 billion investment by Hillhouse Capital.
  • EagleTree Capital acquires IntegreonJones Day advised EagleTree Capital in connection with the acquisition and financing of Integreon, a leading global managed services provider, from NewQuest Capital Partners.
  • Solmax acquires TenCate GeosyntheticsJones Day advised Groupe Solmax Inc. (Solmax), the global leader in the production of high-quality polyethylene geomembranes for industrial and environmental applications, and its shareholders (including institutional investors Caisse de dépot et placement du Québec and Fonds de Solidarité FTQ), in connection with Solmax’s acquisition of TenCate Geosynthetics Holding B.V., a global provider of geosynthetics and industrial fabrics, from Dutch conglomerate Koninklijke Ten Cate (Royal Ten Cate, the Netherlands), and advised on the related senior secured financing to support the acquisition.
  • ETS acquires VericantJones Day advised Educational Testing Service in its acquisition of Vericant, a provider of secure, verified in person interviews and Spoken English Evaluations worldwide.
  • Best Courage Global participates in Series A financing round of Aland Health Holding Ltd.Jones Day represented Best Courage Global Limited in connection with the Series A financing round of Aland Health Holding Ltd., a designer, manufacturer, seller and distributor of vitamins and other health and nutrition supplements and a provider of nutrition management solutions.
  • Successful Lotus Limited makes HK$40 million investment in Ganglong China Property Group LimitedJones Day represented Successful Lotus Limited in making a cornerstone investment in Ganglong China Property Group Limited, whose principal business is the development and sales of properties predominantly for residential use mixed with accompanying ancillary facilities, by way of subscription of shares for HK$40 million.
  • GenScript Biotech Corporation completes US$423.8 million IPO and spin-off of its subsidiary Legend Biotech Corporation; and US$24 million purchase of Ordinary Shares of Legend BiotechJones Day acted as the U.S. and Hong Kong legal advisors of GenScript Biotech Corporation (“GenScript Biotech”) in relation to its (a) approximately US$423.8 million initial public offering of 18,425,000 American Depositary Shares and spin-off listing of its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select Market and (b) approximately US$24 million purchase of Ordinary Shares of Legend Biotech in a concurrent private placement of Legend Biotech.
  • Successful Lotus Limited makes HK$21 million investment in Ye Xing Group Holdings LimitedJones Day represented Successful Lotus Limited in making a cornerstone investment in Ye Xing Group Holdings Limited, whose principal business is the provision of property management and related services for residential and non-residential properties in China, by way of subscription of shares for HK$21 million.
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • The following represents experience acquired prior to joining Jones Day.

    Represented CLSA, Credit Suisse, Haitong International, and Jefferies as placing agents in Guangzhou-based Evergrande Real Estate Group's US$600 million top-up placement.

    Represented Hong Kong Gree Electric Appliances Sales Limited in its US$100 million cornerstone investment in Red Star Macalline Group Corporation's IPO on the Hong Kong Stock Exchange.

    Represented Hong Kong Gree Electric Appliances Sales Limited in its US$200 million cornerstone investment in Dailian Wanda Commercial Properties' IPO on the Hong Kong Stock Exchange. This IPO was one of the most high-profile capital markets transactions in 2014.

    Represented the sole sponsor, Haitong International Capital Limited, and the underwriters, Haitong International Securities Company, J.P. Morgan Securities (Asia Pacific), J.P. Morgan Securities, KGI Capital Asia, and RHB Securities Hong Kong, in relation to life science research and application services company Genscript Biotech Corporation's HK$524million IPO on the Hong Kong Stock Exchange.

    Represented China VAST Industrial Urban Development Company in its US$132 million IPO on the Hong Kong Stock Exchange. China VAST is a leading service provider in the planning, development, and operation of large-scale industrial towns in China, focusing on land areas of 10 million square meters or more.

    Represented China International Capital Corporation (CICC), UBS, and Morgan Stanley as placing agents for Sinopharm Group Co.'s New H-Share placement raising HK$4 billion (approximately US$515 million).

    Represented China International Capital Corporation (CICC) and CITIC Securities as joint underwriters in the US$4 billion A+H Share rights issue of China CITIC Bank Corporation. China CITIC is China's seventh largest lender in terms of total assets.

    Represented China International Capital Corporation, UBS AG, and Morgan Stanley & Co. International (as placing agents) on the US$442.5 million H-share placement of Sinopharm Group Co., the largest distributor of pharmaceutical and health care products in China.

    Represented BOCI Asia Limited and UBS AG (as placing agents) in the US$684 million placing of shares of Sino-Ocean Land Holdings Limited by its shareholder COSCO International Holdings Limited.

    Represented HL Technology Group Limited in its US$65 million initial public offering on the Hong Kong Stock Exchange. Piper Jaffray Asia Securities Limited was the sole lead manager of the transaction.

    Represented Templeton Strategic Emerging Market Fund III, LDC, Sinochem Europe Capital Corporation, CCB International Asset Management, and New World Strategic Investment Limited in their US$35 million investment in ShiFang Holding Limited, an electronic and printed media content provider in Fujian.

    Represented China ITS (Holdings) Co., a leading traffic engineering and intelligent traffic system company in Beijing, in its various rounds of pre-IPO financing, introducing Baring, Investor AB, China Merchant, Temasek Capital (Private) Limited, GE Capital, Intel Capital, Mizuho, and NWS Holdings as shareholders.

    Represented the group of underwriters, which included China International Capital Corporation, UBS AG, Morgan Stanley Asia Limited, Deutsche Bank AG, and Citigroup Global Markets Asia Limited, in the US$1.1 billion initial public offering of Sinopharm Ground Company Limited in Hong Kong. Sinopharm is China's largest distributor of pharmaceuticals and is managed by state-owned China National Pharmaceutical Group. The IPO was awarded "Best IPO of the Year" by FinanceAsia and named as "Best Equity Deal" on IFRAsia's 2009 Roll of Honour.

    Represented the group of underwriters, which included Merrill Lynch Far East Limited and BOCI Asia Limited, in the US$400 million IPO and listing of shares of China South City Holdings, a leading developer and operator of large-scale logistics and trade centers in China, on the Hong Kong Stock Exchange.

    Represented the group of underwriters, which included CITIC Securities Corporate Finance (HK) Limited, UBS AG, J.P. Morgan Securities Ltd., and Macquarie Capital Securities Limited in the US$1,380 million IPO and listing of shares of China Zhongwang Holdings Limited on the Hong Kong Stock Exchange.

    Represented the group of underwriters, which included BOCI Asia Limited, The Hongkong and Shanghai Banking Corporation Limited, Morgan Stanley Asia Limited, and UBS AG, in the US$435 million IPO and listing of shares of Renhe Commercial Holdings Commercial Limited, a leading underground shopping mall developer and operator in China on the Hong Kong Stock Exchange.

    Represented Cazenove Asia Limited (as placing agent) in the HK$388 million placing of H shares of Zhejiang Glass Company (representing 8.9% of the issued share capital of Zhejiang Glass).

    Represented Maoye International Holdings Limited, a leading department store operator, in its US$343 million Hong Kong Stock Exchange initial public offering.

    Represented Kingsoft Corporation Limited, a leading China-based software developer, distributor, and service provider, in its US$115 million IPO on the Hong Kong Stock Exchange.

    Represented China Resources Power Company Limited in its US$626.4 million top-up share placement that raised approximately (HK$4.6 billion) of 200 million shares (with Morgan Stanley & Co. International and Citigroup Global Markets Asia Limited as joint placing agents).